Beyond Air Inc

Beyond Air, Inc. is a clinical-stage medical device and biopharmaceutical company. It engages in developing a nitric oxide generator and delivery system that uses nitric oxide generated from ambient air and delivers precise amounts of nitric oxide to the lungs for the potential treatment of respiratory and other diseases. It operates under the Beyond Air and Beyond Cancer segments. The firm developed the LungFit platform system, a generator and delivery system that produces nitric oxide from ambient air, eliminating the need for expensive and cumbersome cylinders. The company was founded in 2011 and is headquartered in Garden City, NY.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

XAIR reports successful Q1 launch of LungFit PH, faces revenue challenges

XAIR's Q1 2023 performance reflects initial investment in commercial launch and R&D, with a focus on sustainable growth. The company's successful commercial launch of LungFit PH and plans for expansion demonstrate market potential. However, managing revenue expectations and strategic resource allocation present challenges. Anticipated international market expansion and the potential impact of the autism program offer future opportunities.

Beyond Air reports Q2 earnings, anticipates regulatory progress and challenges

Beyond Air's Q2 earnings call highlighted the commercial progress of LungFit PH, financial results, and strategic plans. The company faces challenges with reimbursement and contract signings but sees opportunities in VCAP trials and regulatory discussions.

XAIR anticipates strong revenue growth and market expansion opportunities

Beyond Air Inc's Q3 2023 performance reflected increased expenses and a GAAP net loss, with a focus on product development and market expansion.
Strengths include positive feedback on LungFit PH, strong leadership, and a dedicated commercial team driving successful launches.
Challenges include regulatory delays, hospital contracting issues, and delays in patient studies, requiring strategic resolutions.
Opportunities lie in team expansion, addressing contracting challenges, FDA meetings, and providing guidance for future growth.
headline

Beyond Air Inc reports successful product launch and secures funding

Beyond Air Inc's Q4 2023 earnings call highlighted a successful commercial launch of LungFit PH and debt financing to support growth initiatives.
While facing challenges such as $0 revenue and cash usage, the company aims to optimize operations and drive revenue generation.
Opportunities lie in expanding product offerings, enhancing customer service, and leveraging unique programs like the early-stage autism initiative.
Overall, Beyond Air Inc remains focused on driving commercial success and maintaining a strong market position through strategic initiatives.

Beyond Air Inc reports Q1 revenue growth and strategic financing

Beyond Air Inc's Q1 2024 earnings call highlighted revenue generation, increased expenses, and strategic financing. The company faces challenges in study endpoints and FDA agreements but sees opportunities in product expansions and regulatory approvals.

Beyond Air Inc reports Q2 earnings, eyes growth opportunities

Beyond Air Inc's Q2 2024 earnings call highlighted revenue guidance for FY 2025, strategic partnerships, and progress in research and development across multiple therapeutic areas.
The company's commercial success with LungFit PH, FDA approvals, and ongoing studies demonstrate a commitment to innovation and market growth amidst financial challenges.
Challenges in financial performance, market dynamics, and competition underscore the need for continued strategic planning and operational efficiency to drive sustainable profitability.
With a diversified pipeline, upcoming data releases, and product enhancements, Beyond Air Inc is poised to capitalize on growth opportunities and strengthen its position in the market.

Beyond Air Inc reports revenue growth and regulatory milestones ahead

Beyond Air Inc shows promising revenue growth and market acceptance, supported by new contracts and product demand.
While facing financial losses and regulatory uncertainties, the company's focus on innovation and customer relationships positions it well for future success.
Anticipated FDA decisions, ongoing hospital starts, and strong leadership underpin the company's growth potential and strategic outlook.

Beyond Air Q4: Growth Amid Challenges, Revenue Down

Beyond Air Inc. concluded fiscal Q4 2024 with significant developments and challenges. While the company demonstrated strong product usage and customer retention, it faces hurdles in customer acquisition speed and legal issues. Financially, the substantial net loss and revised down revenue projections highlight areas needing attention.

Beyond Air Inc reports growth in hospital clients and global expansion

Beyond Air Inc's Q2 2025 earnings call highlighted significant achievements, including a surge in hospital clients, strategic partnerships for global expansion, and progress on regulatory approvals for key products. The company showcased a commitment to financial sustainability through cash runway extension and cost reduction measures.
While facing challenges such as regulatory approval delays and a reported net loss, Beyond Air Inc remains focused on innovation and market growth. Opportunities lie in leveraging partnerships, product expansions, and cash reserves to drive future revenue and profitability.
Overall, Beyond Air Inc's performance reflects a mix of strengths, challenges, and opportunities, positioning the company for potential growth and market success. Analyst inquiries during the call underscored a keen interest in contract growth, strategic partnerships, and revenue prospects.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Beyond Air, Inc. is a commercial stage medical device and biopharmaceutical company, which engages in the development of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. It operates through the Beyond Air and Beyond Cancer segments. The company was founded on April 28, 2015 and is headquartered in Garden City, NY.

GARDEN CITY, N.Y., Sept.  11, 2020  (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and gaseous NO for the treatment of solid tumors and tumor metastases, today announced that Steven Lisi, Chairman and Chief Executive Officer of Beyond Air, will participate in the Oppenheimer & Co. Fall Healthcare Life Sciences and MedTech Summit being held virtually from September 21st to 23rd.

Beyond Air to Present at the Oppenheimer & Co. Fall Healthcare Life Sciences and MedTech Summit

GARDEN CITY, N.Y., Sept.  09, 2020  (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and gaseous NO for the treatment of solid tumors and tumor metastases, today announced that two e-poster presentations have been accepted for the CHEST 2020 Annual Meeting, which is being held from October 18th to 21st.

Beyond Air® to Present Posters on CoronaVirus and Bronchiolitis at the CHEST 2020 Annual Meeting

GARDEN CITY, N.Y., Aug.  27, 2020  (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and gaseous NO for the treatment of solid tumors, today announced that an e-poster presentation has been accepted at the International Association for the Study of Lung Cancer’s (IASLC) upcoming North America Conference on Lung Cancer 2020 (NACLC 2020) being held from October 16th to 17th.

Beyond Air® to Present New Nitric Oxide Data in an e-Poster Presentation at the North America Conference on Lung Cancer 2020 (NACLC 2020)

Heterogeneity in M. abscessus susceptibility to NO

Beyond Air Publishes New Data on Nitric Oxide to Treat M. Abscessus  in the Peer-Reviewed Journal Access Microbiology

Beyond Air, Inc. (XAIR) CEO Steve Lisi on Q1 2021 Results - Earnings Call Transcript

Beyond Air Has Huge Long-Term Potential

AIT Therapeutics, Inc. (XAIR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Will AIT Therapeutics, Inc. (XAIR) Report Negative Earnings Next Week?

Conference call at 8:30 a.m. ET Conference call at 8:30 a.m. ET

Beyond Air® to Announce Fiscal First Quarter 2021 Financial Results on Thursday, August 6th

Shares of Beyond Air Inc (NASDAQ:XAIR) rose by 2.9% from the previous closing price.

Insider Buys Beyond Air's Shares

Beyond Air, Inc. (XAIR) CEO Steve Lisi on Q4 2020 Results - Earnings Call Transcript

Reported   positive clinical data for third bronchiolitis study   using high concentration nitric oxide,  achieving primary and key secondary endpoints

Beyond Air Reports Financial Results for Fiscal Fourth Quarter and Year-End 2020

Data demonstrate the ablation of solid tumors with nitric oxide

Beyond Air Announces Positive Preclinical Data Supporting High Concentration Nitric Oxide as a Potential Treatment for Solid Tumors

Analysts Estimate AIT Therapeutics, Inc. (XAIR) to Report a Decline in Earnings: What to Look Out for

GARDEN CITY, N.Y., June  15, 2020  (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and gaseous NO for the treatment of solid tumors, today announced the first patient has been enrolled in the U.S. clinical study using the LungFit™ system to treat COVID-19 with NO therapy. The patient was enrolled at the Baptist Health Center for Clinical Research in Little Rock, Arkansas.

Beyond Air Announces First Patient Enrolled in its U.S. Study of Nitric Oxide Therapy Using the LungFit™ System in COVID-19 Patients

Anticipate study start in June 2020 Anticipate study start in June 2020

Beyond Air Receives Approval from Health Canada to Study Nitric Oxide Generated and Delivered by the LungFit™ in COVID-19 Patients

High concentration nitric oxide (150 ppm) is statistically significant  compared to both low concentration nitric oxide (85 ppm) and control  arms on both the primary endpoint and the key secondary endpoint

Beyond Air Achieves Primary Endpoint in Pilot Bronchiolitis Study

GARDEN CITY, N.Y., May  15, 2020  (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and gaseous NO for the treatment of solid tumors, today announced an e-poster presentation at the upcoming American Association for Cancer Research (AACR) Virtual Annual Meeting II being held from June 22nd to 24th.

Beyond Air™ to Present New Data in an e-Poster Presentation at the Upcoming AACR Virtual Annual Meeting II on June 22nd to 24th

Beyond Air Enters into New Common Stock Purchase Agreement Extending Relationship with Lincoln Park Capital

Food and Drug Administration (FDA) agrees to a trial using  the LungFit ™  system to treat COVID-19 patients

Beyond Air to Initiate Clinical Study Evaluating High Concentration Nitric Oxide for the Treatment of COVID-19 Patients in the United States

Prepared to test LungFit™ BRO in COVID-19 patients in a clinical study starting in April pending FDA approval of recently submitted IDE (investigational device exemption) Prepared to test LungFit™ BRO in COVID-19 patients in a clinical study starting in April pending FDA approval of recently submitted IDE (investigational device exemption)

Beyond Air Accelerates LungFit™ BRO COVID-19 Program

Beyond Air Inc. XAIR, +17.05% said Monday that it submitted an investigational device exemption to the Food and Drug Administration (FDA) as it seeks authority to market its nitric oxide device to treat patients with COVID-19.

Beyond Air seeks exemption from FDA to test device for COVID-19

Beyond Air: Buy The Stock Ahead Of March 5 Analyst Day

Beyond Air, Inc. (XAIR) CEO Steve Lisi on Q3 2020 Results - Earnings Call Transcript

AIT Therapeutics, Inc. (XAIR) delivered earnings and revenue surprises of -30.30% and -45.39%, respectively, for the quarter ended December 2019.

AIT Therapeutics, Inc. (XAIR) Reports Q3 Loss, Lags Revenue Estimates

GARDEN CITY, N.Y. and REHOVOT, Israel, Dec.  18, 2019  (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including serious lung infections and pulmonary hypertension, today announced the termination, for material breach, of the agreement with Circassia Pharmaceuticals, PLC for licensing the commercial rights for LungFit™ PH in the United States and China for use in the hospital setting at NO concentrations

News for Beyond Air Inc Stock (XAIR)